Promising combo tackles rare esophageal cancer before surgery
NCT ID NCT07155122
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving the immunotherapy drug serplulimab along with standard chemotherapy before surgery can help patients with a rare, limited-stage small cell cancer of the esophagus. The study will enroll 15 people and measure how many have no cancer cells left after treatment. The goal is to see if this approach is safe and effective enough to pursue in larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Serplulimab (an immunotherapy drug) combined with etoposide and cisplatin (chemotherapy)
- What this could lead to
- If successful, this could lead to a new treatment option before surgery for a rare and aggressive esophageal cancer, potentially improving outcomes.
- What could go wrong
- This is a very small, early-phase trial with only 15 participants, so results may not apply broadly. The combination may cause significant side effects from both immunotherapy and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL-CELL CARCINOMA OF THE ESOPHAGEAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.